It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

ixCELL-DCM: Stem Cell Study

Clinical Trial Title: 
ixCELL-DCM: A clinical research trial for adults with chronic congestive heart failure (CHF) due to a prior heart attack or coronary artery disease (ischemic dilated cardiomyopathy)
Clinical Trial Protocol ID: 
12012701
Clinical Trial Investigator Name: 
Gary L. Schaer, MD
Clinical Trial Protocol Description: 

This study will assess the safety and efficacy of using stem cells from the patient's own bone marrow to treat CHF due to ischemic dilated cardiomyopathy. Eligible patients will receive stem cells (or placebo) delivered directly to the heart using a minimally invasive catheter technique, with the aim of improving heart function and symptoms of CHF.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are a male or female between the ages of 30 and 86.
  • Have been diagnosed with ischemic dilated cardiomyopathy.
  • Have an automatic implantable cardioverter defibrillator (AICD).
  • Have a left ventricular ejection fraction (measure of heart pumping function) less than 35 percent.

You will be excluded from the study if any of the following criteria apply to you:

  • Have or plan to have a ventricular assist device (VAD) implantation or heart transplant.
  • Have had a myocardial infarction (heart attack), stroke or transient ischemic attack within the last three months.

This is a partial list of eligibility and exclusion criteria. To inquire whether you are eligible for this study, please call the contact number provided. If you choose to inquire via email, please refer to the study title in your correspondence.

Clinical Trial Area: 
Heart and Vascular Conditions
Contact Email: 
Contact Phone: 
(312) 942-8144
Contact Name: 
Jonathan Learoyd